BlackRock Investment Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

BlackRock Investment Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$19K	Hold	1,211	–	–	﹤0.01%	3402
2016 Q3	$16K	Hold	1,211	–	–	﹤0.01%	3424
2016 Q2	$8K	Sell	1,211 -11,019	-90%	-$92.2K	﹤0.01%	3734
2016 Q1	$116K	Buy	12,230 +247	+2%	+$1.99K	﹤0.01%	3225
2015 Q4	$121K	Buy	11,983 +86	+0.7%	+$1.14K	﹤0.01%	3270
2015 Q3	$170K	Buy	+11,897	New	+$292K	﹤0.01%	3261

Other funds holding ZYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

CCMU

Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

AAM

Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Investment Management's ZYNE Position: Q4 2016 in Review

BlackRock Investment Management held its Zynerba Pharmaceuticals, Inc (ZYNE) position steady in Q4 2016 at 1,211 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #3402.

BlackRock Investment Management first reported a position in ZYNE in Q3 2015 and has held it in 6 quarters since. The position peaked at $170K in Q3 2015. 34 funds tracked by Wall St. Rank hold ZYNE as of Q4 2016.

BlackRock Investment Management held 1,211 shares of Zynerba Pharmaceuticals, Inc worth $19K as of Q4 2016.
BlackRock Investment Management left its Zynerba Pharmaceuticals, Inc share count unchanged in Q4 2016.
Zynerba Pharmaceuticals, Inc made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3402 holding.
BlackRock Investment Management first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and has held it in 6 quarters since.
BlackRock Investment Management's Zynerba Pharmaceuticals, Inc position peaked at $170K in Q3 2015.
34 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.